SOURCES:
National Cancer Institute: “Stopping Multiple Myeloma with New Treatments,” “Pomalidomide for Multiple Myeloma,” “Drugs Approved for Multiple Myeloma,” “New Use for Lenalidomide in Multiple Myeloma.”
Up to Date: “Patient education: Multiple myeloma treatment (Beyond the Basics).”
Hans C. Lee, MD, assistant professor, University of Texas MD Anderson Cancer Center.
Blood: “Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.”
FDA: “FDA grants accelerated approval to selinexor for multiple myeloma,” “FDA Approves First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma,” “FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma.”
Mayo Clinic: “Monoclonal antibody drugs for cancer: how they work.”
Drugs: “Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma.”
The New England Journal of Medicine: “Elotuzumab Plus Pomalidomide and Dexamethasone for Multiple Myeloma.”
National Cancer Institute: “FDA Approves New Use for Daratumumab in Multiple Myeloma,” “FDA Approves Panobinostat for Some Patients With Multiple Myeloma.”
International Myeloma Foundation: “Darzalex (Daratumumab),” “Ninlaro (Ixazomib),” “Belantamab mafodotin anti-BCMA ADC.”
Multiple Myeloma Research Foundation: “Standard Treatments.”
Frontiers in Immunology: “Therapeutic Bi-specific T-cell Engager Antibody Targeting the Transferrin Receptor.”